Research Papers:
Silencing of R-Spondin1 increases radiosensitivity of glioma cells
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2094 views | HTML 2473 views | ?
Abstract
Xuefeng Gu1,2,*, Xuefeng Wang3,*, Hong Xiao3,*, Guoda Ma1, Lili Cui1, You Li2, Haihong Zhou4, Wandong Liang5, Bin Zhao2, Keshen Li1
1Institute of Neurology, Guangdong Medical College, Zhanjiang 524001, China
2Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China
3Department of Neurosurgery, Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China
4Department of Neurology, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China
5Renji College, Wenzhou Medical University, Wenzhou 325000, China
*These authors have contributed equally to this work
Correspondence to:
Keshen Li, e-mail: [email protected]
Bin Zhao, e-mail: [email protected]
Keywords: Rspo1, glioma, radiation
Received: December 22, 2014 Accepted: February 17, 2015 Published: March 12, 2015
ABSTRACT
Although radiation therapy is the most effective postoperative adjuvant treatment, it does not substantially improve the long-term outcomes of glioma patients because of the characteristic radioresistance of glioma. We found that R-Spondin1 (Rspo1) expression was elevated in high-grade gliomas and was associated with worse overall survival and disease-free survival. Rspo1 expression was also associated with reduced survival rates in glioma patients after treatment with radiotherapy and temozolomide (RT-TMZ). Importantly, Rspo1 was dramatically upregulated after radiation treatment in patients with glioma. Rspo1 silencing by shRNA potentiated glioma cell death upon radiation treatment. In a xenograft nude mouse model, combining radiation and silencing of Rspo1 potentiated tumor growth inhibition. Thus, combining radiotherapy with silencing of Rspo1 is a potential therapeutic approach.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3395